This will be 1 July 2021 for consideration at the November 2021 meeting. Please see relevant pages for information.
The Kay Kendall Leukaemia Fund awards grants for research on aspects of leukaemia and for relevant studies on related haematological malignancies. Applications are sought for first class research on innovative proposals and are particularly welcomed from those with applications close to the care of leukaemia patients or the prevention of leukaemia or related diseases.
There is a preference to support centres of excellence or those with an established international reputation in the field.
Funding decisions will be based on the calibre of the applicant, the scientific merit and originality of the proposal and the excellence of the host institution, together with recommendations from peer reviewers and the Fund’s Scientific Advisers.
In 2008 Trustees instigated a new programme of patient care and patient centred projects associated with leukaemia and haematological diseases. Patient care proposals are generally invited or initiated by the Trustees, however, the Fund would wish to be made aware of significant appeals, capital builds, or other initiatives with a strong patient-care focus for leukaemia patients, their families, and carers.
The Kay Kendall Leukaemia Fund’s last year of active granting will be 2021/22.
Professor Vincenzo Cerundolo FRS
Trustees were very sad to hear of the death of Professor Vincenzo (Enzo) Cerundolo FRS. Professor Cerundolo was Professor of Immunology and Director of the MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford. Enzo was a Scientific Adviser to KKLF from 2012, and contributed greatly to the work of the Charity and he will be very much missed. For further information on Professor Cerundolo please see this link to the WIMM.
The Kay Kendall Leukaemia Fund is one of 17 different independent grant-making trusts established by members of three generations of the Sainsbury family. Each trust is an independent legal entity with its own separate and autonomous board of trustees.
The Kay Kendall Leukaemia Fund is registered as a data controller with the UK Information Commissioner’s Office.